{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:51Z","timestamp":1789628511075,"version":"build-2803163510"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aims to conduct a systematic evaluation of the efficacy and safety of adalimumab (ADA) in treating psoriatic arthritis (PsA), providing evidence-based reference data for clinical medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed, Embase, Web of Science, the Cochrane Library, as well as Chinese databases, including China National Knowledge Infrastructure, WanFang Data, and VIP Chinese Scientific Journals Database, to identify relevant randomized controlled trials of ADA for PsA. The final search was updated on June 10, 2026. Data were analyzed using Stata 15.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This meta-analysis involved 17 studies, including 1 phase II clinical trial and 11 phase III clinical trials, covering 5655 patients. According to the meta-analysis, ADA demonstrated significant improvements in ACR20 (risk ratio [RR]: 2.27, 95% confidence interval [CI]: 1.83\u20132.83), ACR50 (RR: 3.92, 95% CI: 2.98\u20135.15), and ACR70 (RR: 5.75, 95% CI: 4.47\u20137.39) among PsA patients compared with the control group. In addition, it also improved PASI75 (RR: 7.07, 95% CI: 4.36\u201311.46), PASI90 (RR: 4.27, 95% CI: 1.64\u201311.14), and PASI100 (RR: 8.23, 95% CI: 3.89\u201317.40). Furthermore, ADA was associated with improvements in other relevant indicators, including PsA response criteria (RR: 2.45, 95% CI: 2.01\u20132.99), complete resolution of enthesitis (RR: 1.46, 95% CI: 1.22\u20131.74), and minimal disease activity (RR: 3.10, 95% CI: 2.58\u20133.73). The study also performed subgroup analyses for outcomes at different stages and dosing intervals. The results showed that there was no significant increase in the overall risk of adverse events (AEs; RR\u2005=\u20051.04) or serious AEs (RR\u2005=\u20051.13), and there was no notable increase in discontinuations due to AEs (RR\u2005=\u20051.46). In the context of specific AEs, ADA was associated with 11 types of AEs but showed almost no impact on the other 6 AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ADA demonstrated beneficial efficacy in treating PsA, as evidenced by improvements in relevant indicators. Meanwhile, ADA demonstrated overall clinical efficacy; however, it was associated with a significantly increased risk of elevated liver enzymes (alanine aminotransferase and aspartate aminotransferase), suggesting a potential signal of hepatotoxicity. While no increase in overall or serious AEs was observed, liver function monitoring may be warranted during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050295","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:05:50Z","timestamp":1787331950000},"page":"e50295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety evaluation of adalimumab for psoriatic arthritis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8244-601X","authenticated-orcid":false,"given":"Zhiyue","family":"Cai","sequence":"first","affiliation":[{"name":"The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Materials Science and Engineering, China University of Petroleum (East China), Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.medcli.2022.01.024","article-title":"Psoriatic arthritis.","volume":"159","author":"L\u00f3pez-Ferrer","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/iji.12127","article-title":"IL-23R gene polymorphism rs2201841 is associated with psoriatic arthritis.","volume":"41","author":"Popadic","year":"2014","journal-title":"Int J Immunogenet"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/jid.2009.169","article-title":"Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.","volume":"129","author":"Duffin","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies.","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.37853","article-title":"Tumor necrosis factor \u03b1 induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.","volume":"65","author":"Lee","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"1545284","DOI":"10.3389\/fimmu.2025.1545284","article-title":"Immune cells differentiation in osteoarthritic cartilage damage: friends or foes?","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/ijms23031481","article-title":"Role of the interaction of tumor necrosis factor-\u03b1 and tumor necrosis factor receptors 1 and 2 in bone-related cells.","volume":"23","author":"Kitaura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"e10409","DOI":"10.1002\/jbm4.10409","article-title":"Macrophages switch to an osteo-modulatory profile upon RANKL induction in a medaka (Oryzias latipes) osteoporosis model.","volume":"4","author":"Phan","year":"2020","journal-title":"JBMR Plus"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00508-016-1111-9","article-title":"An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets.","volume":"128","author":"Kerschbaumer","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis.","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20260917","first-page":"S94","article-title":"The role of methotrexate in psoriatic arthritis: what is the evidence?","volume":"33","author":"Ianculescu","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.3390\/ijms24076384","article-title":"Targeted therapies in psoriatic arthritis-an update.","volume":"24","author":"Sundanum","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/biomedicines10020498","article-title":"Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action.","volume":"10","author":"Mohd Noor","year":"2022","journal-title":"Biomedicines"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40744-022-00514-0","article-title":"Sequencing of biologic and target synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A perspective.","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"1759720X241240913","DOI":"10.1177\/1759720X241240913","article-title":"The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial.","volume":"16","author":"Watson","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy.","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S14569","article-title":"The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents.","volume":"4","author":"Reimold","year":"2012","journal-title":"Open Access Rheumatol"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view.","volume":"288","author":"Hu","year":"2013","journal-title":"J Biol Chem"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/S2665-9913(23)00070-X","article-title":"Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.","volume":"5","author":"Tamai","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.12499","article-title":"Adalimumab maintains remission of Crohn\u2019s disease after up to 4 years of treatment: data from CHARM and ADHERE.","volume":"38","author":"Panaccione","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1093\/ibd\/izab260","article-title":"Successful treatment of ulcerative colitis, rectovaginal fistula, and skin erythema nodule with adalimumab.","volume":"28","author":"Dai","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis.","volume":"268","author":"Pichi","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040622318772705","article-title":"Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.","volume":"9","author":"Sator","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s42358-024-00361-3","article-title":"Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.","volume":"64","author":"Montezuma","year":"2024","journal-title":"Adv Rheumatol"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R34-20260917","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ard.2008.091389","article-title":"A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.","volume":"68","author":"van Kuijk","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R38-20260917","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R39-20260917","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R40-20260917","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R41-20260917","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis.","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-20260917","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate.","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R43-20260917","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/rheumatology\/key161","article-title":"Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-na\u00efve patients with active psoriatic arthritis (SPIRIT-P1).","volume":"57","author":"Gottlieb","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R44-20260917","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"R45-20260917","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis.","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"R46-20260917","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1.","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R47-20260917","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"R48-20260917","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R49-20260917","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis.","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R50-20260917","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis.","volume":"72","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R51-20260917","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5114\/reum\/189779","article-title":"The problem of residual pain in the assessment of rheumatoid arthritis activity.","volume":"62","author":"Motyl","year":"2024","journal-title":"Reumatologia"},{"key":"R52-20260917","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-020-02394-7","article-title":"Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.","volume":"23","author":"Kay","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R53-20260917","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","article-title":"Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.","volume":"74","author":"Ward","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R54-20260917","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-018-0011-1","article-title":"Network meta-analysis and cost per responder of targeted immunomodulators in the treatment of active psoriatic arthritis.","volume":"2","author":"Strand","year":"2018","journal-title":"BMC Rheumatol"},{"key":"R55-20260917","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/09546634.2020.1747590","article-title":"Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.","volume":"33","author":"Gordon","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R56-20260917","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","article-title":"Absolute and relative Psoriasis Area and Severity Index (PASI) treatment goals and their association with health-related quality of life.","volume":"31","author":"Gerdes","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R57-20260917","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jid.2021.12.036","article-title":"TNFR2 depletion reduces psoriatic inflammation in mice by downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23\/IL-17 pathways.","volume":"142","author":"Chandrasekharan","year":"2022","journal-title":"J Invest Dermatol"},{"key":"R58-20260917","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints.","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R59-20260917","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis.","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R60-20260917","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R61-20260917","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.","volume":"41","author":"Orbai","year":"2014","journal-title":"J Rheumatol"},{"key":"R62-20260917","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1136\/rmdopen-2019-001002","article-title":"Measurement properties of the minimal disease activity criteria for psoriatic arthritis.","volume":"5","author":"Coates","year":"2019","journal-title":"RMD Open"},{"key":"R63-20260917","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3899\/jrheum.120970","article-title":"Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.","volume":"40","author":"Mease","year":"2013","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:02Z","timestamp":1789624922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050295"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":63,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050295","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}